Misplaced Pages

Allisartan isoproxil

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 22:39, 3 January 2025 (Add: pmid, doi-access, pmc, doi, pages, issue, volume, journal, title, date, authors 1-8. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 22:39, 3 January 2025 by Citation bot (talk | contribs) (Add: pmid, doi-access, pmc, doi, pages, issue, volume, journal, title, date, authors 1-8. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_toolbar)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Allisartan isoproxil
Identifiers
IUPAC name
  • Propan-2-yloxycarbonyloxymethyl 2-butyl-5-chloro-3-phenyl]methyl]imidazole-4-carboxylate
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC27H29ClN6O5
Molar mass553.02 g·mol
3D model (JSmol)
SMILES
  • CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCOC(=O)OC(C)C)Cl
InChI
  • InChI=1S/C27H29ClN6O5/c1-4-5-10-22-29-24(28)23(26(35)37-16-38-27(36)39-17(2)3)34(22)15-18-11-13-19(14-12-18)20-8-6-7-9-21(20)25-30-32-33-31-25/h6-9,11-14,17H,4-5,10,15-16H2,1-3H3,(H,30,31,32,33)
  • Key:XMHJQQAKXRUCHI-UHFFFAOYSA-N

Allisartan isoproxil is an antihypertensive pharmaceutical drug. It belongs to the angiotensin II receptor blocker class of drugs. It is an esterified prodrug, and its metabolism results in the formation of a single metabolite, losartan carboxylic acid (EXP3174), an oxidized form of losartan.

Chemical structure of losartan carboxylic acid

In China, allisartan isoproxil was approved by the Chinese Food and Drug Administration for the treatment of hypertension in 2012, and introduced to the market in 2013.

References

  1. Zhang, J. Q.; Yang, G. H.; Zhou, X.; Liu, J. X.; Shi, R.; Dong, Y.; Chen, S. B.; Li, Y. M. (2019). "Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension". Medicine. 98 (12): e14907. doi:10.1097/MD.0000000000014907. PMC 6708765. PMID 30896643.
  2. Zhao, F.; Liu, Y.; Chen, L. (2024). "Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: A meta-analysis". Frontiers in Cardiovascular Medicine. 11. doi:10.3389/fcvm.2024.1355014. PMC 11187348. PMID 38903964.
  3. Wang, H.; Xi, Y.; Chen, Y.; Wang, L.; Yang, F.; Lu, X.; Sun, N. (2023). "Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension". American Journal of Hypertension. 36 (10): 561–567. doi:10.1093/ajh/hpad055. PMID 37343187.
  4. Zhao, F.; Liu, Y.; Chen, L. (2024). "Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: A meta-analysis". Frontiers in Cardiovascular Medicine. 11. doi:10.3389/fcvm.2024.1355014. PMC 11187348. PMID 38903964.
  5. Ling, Qi-Sheng; Zhang, Sai-Long; Tian, Jia-Sheng; Cheng, Ming-he; Liu, Ai-jun; Fu, Feng-hua; Liu, Jian-guo; Miao, Chao-yu (2021). "Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage". Acta Pharmacologica Sinica. 42 (6): 871–884. doi:10.1038/s41401-021-00684-7. PMC 8149727. PMID 34002042.
Categories: